Pharma Fusion and Santa Rosa Pharmacy Forge Strategic Merger, Creating a Next-Generation National Specialty Pharmacy Platform Expanding high-touch care for patients with bleeding disorders, immunoglobulin therapies, and hereditary angioedema
LAKE CHARLES, LA / ACCESS Newswire / April 1, 2026 / Pharma Fusion announced today, it has entered into a Strategic Merger Agreement with Santa Rosa Pharmacy, uniting two specialty pharmacy leaders under a single, patient-centered platform.
The combined integration creates a scaled, national specialty pharmacy with deep clinical expertise in bleeding disorders, immunoglobulin (Ig) therapies, and hereditary angioedema (HAE), designed to deliver high-touch care for patients living with complex and rare disorders with expensive biological therapies.
The integration amplifies a shared mission: providing deeply personalized specialty pharmacy services for patients requiring advanced therapies. By bringing together complementary clinical strengths, operational infrastructure, and patient centric care models, the unified Pharma Fusion organization significantly enhances its ability to support patients, healthcare providers, and partners across the United States.
Combined, the new Pharma Fusion is projected to generate revenues of more than $130 million in 2026, positioning the company as a fast-growing, innovation focused player in the specialty pharmacy space.
National Reach and Clinical Scale
A core driver of the merger is the powerful, expanded geographic reach created through the integration of both organizations.
Together, the combined entity will operate with licensing coverage across 49 U.S. states and three U.S. territories, including Puerto Rico, Guam, and Saipan, with active plans underway to secure licensure in the 50th state and additional U.S. territories, such as the U.S. Virgin Islands.
This expanded national footprint helps remove geographic barriers that too often limit access to specialty care, ensuring that patients with rare and complex diseases can receive consistent, expert clinical support regardless of where they live. For patients and partners, the new Pharma Fusion represents a single, unified platform capable of delivering high-touch specialty pharmacy care at true national scale.
Leadership Alignment and Continuity
In Pharm Fusion the fusion of the merger reflects strong alignment between the leadership teams and ensures continuity for patients, providers, and healthcare partners.
Dr. Sajal Roy, formerly Chief Executive Officer of Pharma Fusion, will transition to Chairman of the Board, focusing on long-term strategic initiatives and organizational growth.
Dr. Rick Rodrigue will serve as Chief Executive Officer of the combined Pharma Fusion organization, leading continued growth, innovation, and operational excellence.
Nicholas Self will continue as Chief Operations Officer, overseeing operational integration and the development of specialized disease-state programs.
Caitlin Henderson will continue serving as Chief Administrative Officer, driving administrative alignment and scalable enterprise support.
Guillermo Campillo will serve as Chief Experience Officer, strengthening the organization's commitment to high-touch specialty care and an exceptional patient and provider experience.
"This integration represents a natural evolution for both organizations," said Dr. Rick Rodrigue, Chief Executive Officer of Pharma Fusion. "By aligning our teams and resources, we are expanding our ability to support patients with complex conditions across nearly the entire United States, while preserving the personalized care both organizations are known for and deploying our AI initiative, Specialty Intelligence™."
Strategic Vision and Specialty Intelligence™
At the center of the combined company's strategy is Pharma Fusion's Specialty Intelligence™ approach, which integrates clinical expertise, proactive care coordination, and personalized patient engagement to help improve outcomes for patients requiring complex specialty therapies. This includes a proprietary AI system that reviews patient health score statistics and generates insights that are highly relevant to insurance companies, PBMs, physicians, hospital systems, pharmaceutical manufacturers, and Medicare.
By analyzing prescribing habits in the rare disease space and identifying the most cost effective strategies and not limited to drug cost alone the Specialty Intelligence™ platform helps stakeholders make smarter, data-driven decisions. The result is a more efficient, more transparent, and more sustainable specialty care ecosystem that protects both patient outcomes and healthcare resources.
There will be no disruption to patient care as a result of the integration. Patients, providers, and healthcare partners will continue working with the same experienced clinical and operational teams they trust today, now backed by a larger, more capable national infrastructure, that is trusted in the industry.
About Pharma Fusion
Pharma Fusion is a specialty pharmacy organization dedicated to improving health outcomes for patients living with rare and complex conditions, with locations in Lake Charles, LA and Bullhead City, AZ. Through its Specialty Intelligence™ approach, the organization integrates clinical expertise, proactive care coordination, and personalized patient engagement to support individuals navigating specialty therapies across the United States.
About Santa Rosa Pharmacy
Santa Rosa Pharmacy, based in Santa Rosa Beach, FL, is a clinical specialty pharmacy known for its personalized patient care and expertise in managing complex therapies. The pharmacy supports patients and healthcare providers nationwide through high-touch specialty pharmacy services.
Media Contact
Caitlin Henderson
510-407-5561
chenderson@pharmafusionrx.com
SOURCE: Pharma Fusion
View the original press release on ACCESS Newswire
